Core Insights - Analysts project Bausch + Lomb (BLCO) will report quarterly earnings of $0.35 per share, reflecting a 40% year-over-year increase [1] - Revenue is expected to reach $1.38 billion, marking an 8.1% increase from the same quarter last year [1] - The consensus EPS estimate has remained unchanged over the past 30 days, indicating analysts' reassessment of projections [1] Revenue Estimates - 'Revenues- Vision Care' are projected to be $780.35 million, representing a year-over-year change of +7.9% [4] - 'Revenues- Pharmaceuticals' are estimated at $355.40 million, indicating a +9% change from the previous year [4] - 'Revenues- Product sales' are expected to total $1.37 billion, reflecting a +7.6% year-over-year change [4] Other Revenue Metrics - 'Revenues- Other revenues' are anticipated to reach $5.00 million [5] - 'Revenues- Surgical' are projected at $248.04 million, suggesting a +7.4% year-over-year increase [5] - Bausch + Lomb shares have decreased by -0.8% over the past month, compared to the Zacks S&P 500 composite's -1.7% [5]

Summary of Lepu's 3Q25 Earnings Call Company Overview - **Company**: Lepu (300003.SZ) - **Industry**: Medical devices and pharmaceuticals in China Key Financial Results - **Revenue**: Rmb1,569 million, up 12% year-over-year, but missed Goldman Sachs estimates (GSe) of Rmb1,937 million due to softer pharmaceutical sales growth of 53% year-over-year compared to GSe's expectation of 70% [1][9] - **Net Profit**: Rmb291 million, up 176% year-over-year, in line with GSe's estimate of Rmb277 million [1][9] - **Selling Expense Ratio**: 17.3%, lower than GSe's estimate of 21.6% [1][9] Business Segments - **Medical Aesthetics**: Generated Rmb86 million in revenue from just two months of sales since August, with management reaffirming a full-year guidance of Rmb300 million for this segment [1][9] - **Future Projections**: Expected revenue from medical aesthetics to reach Rmb1 billion by 2026 [1][9] Product Development and Pipeline - **PDRN Product and Thermage**: Anticipated approval in Q1/Q2 of the following year [1][9] - **Innovative Drug Pipeline**: Two new assets added, with existing assets progressing as planned [1][9] Forecast Revisions - **Short-term Revenue Forecast**: Slightly lowered to reflect 3Q25 results [1][9] - **Long-term Revenue and Net Profit Forecast**: Increased due to optimistic R&D progress in innovative drugs [1][9] - **Updated Price Target**: Raised to Rmb19 from Rmb18, maintaining a Buy rating [1][9] Investment Thesis - **Market Position**: Lepu is positioned as a cardiovascular disease treatment and diagnostics solution provider, expanding into consumer medical products [1][9] - **Concerns**: Investors are wary due to the impact of the volume-based procurement (VBP) policy and anti-corruption campaigns affecting revenue growth [1][9] - **Long-term Growth Potential**: Innovative products and the medical aesthetic business are expected to offset revenue losses from VBP, providing long-term growth momentum [1][9] Key Catalysts 1. Successful launch of innovative products in 2025 2. Rapid ramp-up of pulsed sonic balloons and degradable PFO occluders, and TAVR [1][9] Risks - **Price Cuts**: Potential price reductions for innovative medical devices due to VBP [1][10] - **R&D Progress**: Risks associated with slower-than-expected R&D progress [1][10] - **Goodwill Impairment**: Possible losses from lower-than-expected earnings from subsidiaries [1][10]

Core Viewpoint - Abbott Laboratories' recent price drop is seen as a buying opportunity, with analysts and institutional investors showing increasing interest in the stock [3][4]. Group 1: Stock Performance and Analyst Sentiment - Abbott Laboratories' stock price is currently at $127.31, with a 52-week range between $110.86 and $141.23, and a dividend yield of 1.85% [3]. - Analyst trends indicate a positive sentiment, with a consensus forecast predicting a 10% gain ahead of the earnings release, potentially reaching an all-time high [4]. - Institutional investors have been consistently purchasing Abbott's stock, with a buying ratio of approximately $1.50 for every $1.00 sold over the past year, increasing to $3.25 to $1 as of mid-October [4]. Group 2: Financial Performance - Abbott's Q3 revenue growth was slightly below analysts' expectations, missing the consensus forecast by 0.17%, but still reported a 6.9% revenue growth [8][10]. - The company achieved a 12.5% organic growth in Medical Devices and 7.1% in Established Pharmaceuticals, while Diagnostics saw a decline of 7.8% due to COVID-19-related sales [10]. - Adjusted operating margin increased by 40 basis points, with operating earnings rising by 10.6% and net income growing by 7.5%, resulting in an adjusted EPS of $1.30, up 7.45% year-over-year [11]. Group 3: Dividend and Growth Outlook - Abbott Laboratories has a reliable dividend yield of 1.85%, with an annual dividend of $2.36 and a track record of 54 years of dividend increases [12][13]. - The company maintains a low dividend payout ratio of 29.57%, indicating strong earnings growth potential, with projections of low-double-digit growth over the next five years [13]. - Abbott's diversified product portfolio across various segments helps mitigate risks from sector-specific slowdowns, positioning the company well for sustained growth and shareholder returns [14].

Investor Presentation May 2025 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management's current expectations, assumptions, estimates and beliefs. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are ba ...